THAR - Tharimmune Corp Sotuvning sof marjinal rentabelligi

THAR (Tharimmune) - kompaniyaning tovar belgisi

Yuqori tebranishlar va sinovlarning erta bosqichlarida muvaffaqiyatsizlikka uchrash xavfi Tharimmune, Inc. (THAR) kompaniyasiga moliyaviy bosim o'tkazmoqda. Ushbu GURU.Markets grafigida ko'rsatilganidek, o'rtacha savdo marjasi kapital samaradorligini namoyish etadi, bunda 0.00 joriy metrika darajasi vazifasini o'taydi. Kompaniyaning salohiyati noelastik talabga ega bo'lgan noyob oral antitelarga asoslangan, AQShdagi geosiyosiy tahdidlarning yo'qligi esa huquqiy barqarorlikni kafolatlaydi.

Tharimmune, Inc. (THAR) Sof foyda bo'yicha sotuv rentabelligi: 21.02.2024 - 18.02.2026 davri uchun

THAR (Tharimmune Corporation): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- bozor qiymati va tahlilchilarning maqsadli prognozi:
Kompaniyaning jamlanma tahlili:Tharimmune Corporation - THAR
Tharimmune Corp tayyor mahsulotlari

Tharimmune, Inc. laboratoriya robototexnikasi va bashorat qiluvchi dasturiy ta'minotni joriy etish orqali molekulalarni skrining qilishni optimallashtirmoqda. Ushbu texnologik xarajatlar sof foydaning umumiy daromadga nisbatiga bevosita ta'sir ko'rsatadi. Ushbu koeffitsient barcha xarajatlardan keyin daromadning har bir dollari qancha qolishini belgilaydi. Operatsion sof foyda marjasining tahlili jarayonlarni avtomatlashtirish samaradorligini aniqlash imkonini beradi. Ushbu ko'rsatkichning tendentsiyasi investorlarga zarar ko'rish xavflarini o'z vaqtida kuzatishga yordam beradi.

Raqobatdosh kompaniyalar tahlili

ONC: Sotuvning sof marjinal rentabelligi|Sof marja Halozyme Inc. (HALO)|Sof marja RevMed|Sotuvning sof rentabelligi AAPG (Ascentage Pharma Group)|Sotuvning sof marjinal rentabelligi CGON|UroGen Pharma - Sotuvning sof rentabelligi|Bicara Therapeutics - Sof foyda bo'yicha sotuv rentabelligi|Sotuvning sof marjinal rentabelligi Personalis Inc PSNL|Erasca Oncology - Sotuvning sof marjinal rentabelligi|Sof foyda normasi DCTH (Delcath Corp)|YMAB: Sotuvning sof marjinal rentabelligi|AURA - Kompaniya sotuv marjasi|CADL (Candel Therapeutics Inc.) - Sotuvning sof marjinal rentabelligi|Sotuvning sof rentabelligi ARAY (Accuray)|Sof foyda bo'yicha sotuv rentabelligi SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Sof marja|Sof marja Citius Oncology, Inc. CTOR|HURA - Sof foyda bo'yicha sotuv rentabelligi|protaratx.com - Sotuvning sof marjinal rentabelligi|FATE - Sotuvning sof marjinal rentabelligi|WHWK: Sotuvning sof marjinal rentabelligi|TScan Therapeutics (TCRX) - Sotuvning sof marjinal rentabelligi|Sof marja Champions Oncology|Sof marja XBIT|Sotuvning sof marjinal rentabelligi CVM|Sof foyda bo'yicha sotuv rentabelligi OS Therapies Inc. OSTX|Sof marja Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Sof marja|ANL - Sof marja|Sof marja verupharma.com|TPST: Sotuvning sof marjinal rentabelligi|XLO - Kompaniya sotuv marjasi|Sof marja Renovaro|Sotuvning sof marjinal rentabelligi muraloncology.com|Sotuvning sof marjinal rentabelligi KAPA|Kompaniya sotuv marjasi OnKure Therapeutics, Inc.|Sotuvning sof marjinal rentabelligi GDTC (w2.cytomed.sg)|CRIS - Sof foyda bo'yicha sotuv rentabelligi|Apollomics - Sotuvning sof marjinal rentabelligi|ADVB: Sof marja|GNPX: Sotuvning sof marjinal rentabelligi|CLDI (Calidi Biotherapeutics Inc.) - Sof marja|Sof marja Sunshine Biopharma, Inc.|Sotuvning sof marjinal rentabelligi xeneticbio.com|Sof marja Salarius (SLRX)|Sof foyda bo'yicha sotuv rentabelligi Purple Biotech PPBT|Sof marja American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Sof marja|Checkpoint Therapeutics Inc. - Sotuvning sof marjinal rentabelligi|Sof foyda normasi ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Sof foyda bo'yicha sotuv rentabelligi|Ikena Oncology, Inc. - Sof foyda normasi|Sof foyda bo'yicha sotuv rentabelligi NTBL|VIRX: Sof foyda normasi|Sof marja MorphoSys Corporation (MOR)|NAYA - Sof marja|Sotuvning sof marjinal rentabelligi AAPGV (Ascentage)